terb2 Antibody

What is TERB2 and why is it important in fertility research?

TERB2 (Telomere Repeat Binding Bouquet Formation Protein 2) is a critical component of the meiotic telomere complex that includes TERB1 and MAJIN. This complex tethers telomere ends to the nuclear envelope and transmits cytoskeletal forces via the LINC complex to drive rapid chromosome movements during meiotic prophase . Recent research has identified biallelic variants in TERB2 associated with non-obstructive azoospermia (NOA) in men, indicating its essential role in male fertility . Specifically, compound heterozygous frameshift variants in TERB2 were identified in three brothers affected by NOA, providing strong evidence for its importance in spermatogenesis .

How do I validate the specificity of a TERB2 antibody?

To validate TERB2 antibody specificity, a multi-step approach is recommended:

• Test the antibody on tissues known to express TERB2 positively (primarily testicular tissue) and negatively (non-germline tissues)

• Perform western blotting using mouse testis samples, as TERB2 is specifically expressed in germline tissues

• Include appropriate controls such as:

  • TERB2 knockout samples if available

  • Competitive binding with the immunizing peptide

  • Comparison with alternative TERB2 antibodies

Expression analysis should confirm that TERB2 is specifically detected in testis fractions, as demonstrated in various species including the basal metazoan Hydra vulgaris .

What are the known structural characteristics of TERB2 that might affect antibody recognition?

TERB2 contains two highly conserved domains that may impact antibody recognition :

• The N-terminal domain (amino acids 1-116 in mouse) shows prominent conservation across species and mediates interaction with TERB1

• The C-terminal region (amino acids 174-209 in mouse) contains conserved stretches important for MAJIN interaction

Of particular interest is a conserved motif [F/YxLxP] at positions 86-90 in human and mouse TERB2, potentially involved in binding to the TRFH domain of telomeric proteins TRF1 and TRF2 . Antibodies targeting these highly conserved epitopes may offer better cross-species reactivity but could potentially interfere with protein-protein interactions.

How should I design immunofluorescence experiments to study TERB2 localization during meiosis?

For optimal TERB2 localization studies during meiosis:

• Sample preparation:

  • Use testicular spreads or sections from appropriate developmental stages

  • For mouse, samples from 2-week-old testes are ideal for studying early meiotic events

• Co-staining markers:

  • Include SYCP3 as a marker for the synaptonemal complex

  • Co-stain with TERB1 and MAJIN to visualize the complete meiotic telomere complex

  • TRF1 as a telomere marker

• Fixation and permeabilization:

  • 4% paraformaldehyde fixation followed by 0.2% Triton X-100 permeabilization

  • Avoid harsh fixation that might mask the TERB2 epitope

• Imaging considerations:

  • Use structured illumination microscopy for high-resolution studies of telomere attachment sites

  • Conventional confocal microscopy is sufficient for co-localization studies

Studies have shown that TERB2 localizes to telomere attachment sites at the nuclear envelope during meiotic prophase I .

What controls should be included when using TERB2 antibodies for co-immunoprecipitation experiments?

For rigorous co-immunoprecipitation experiments with TERB2 antibodies:

• Essential controls:

  • Input sample (5-10% of lysate used for IP)

  • Non-specific IgG from the same species as the TERB2 antibody

  • Beads-only control

  • Reciprocal IP using antibodies against interacting partners (TERB1, MAJIN)

• Validation strategies:

  • Use lysates from cells expressing tagged TERB2 constructs (FLAG-TERB2 or GFP-TERB2) for verification

  • Include samples with disrupted interaction interfaces (e.g., TERB2 Y56E mutant for TERB1 interaction, F192R mutant for MAJIN interaction)

• Stringency conditions:

  • Test multiple wash buffer stringencies to confirm specific interactions

  • For the TERB2-MAJIN interaction, which appears to be stronger than TERB2-TERB1, higher stringency may be required

Research has demonstrated that GFP-Trap or Anti-FLAG M2 Affinity Gel can be used effectively for these experiments .

What is the best approach for detecting TERB2 expression in different tissues or developmental stages?

For comprehensive TERB2 expression analysis:

• RNA analysis:

  • Perform RT-PCR using primers spanning exon-exon junctions

  • Design primers for conserved regions to ensure specificity

  • Use quantitative PCR for relative expression levels across tissues

  • Include positive controls (testis tissue) and negative controls

• Protein detection:

  • Western blotting with validated TERB2 antibodies

  • Normalize loading with housekeeping genes appropriate for reproductive tissues

  • Include multiple developmental timepoints for spermatogenesis studies

• Spatial expression:

  • Whole mount in situ hybridization (WMIH) for spatial localization in intact tissue

  • Use SYCP3 as a specific marker of meiotic cells for comparison

Expression studies have shown that TERB2 is specifically detected in testis tissue and localizes to meiotic cells, as demonstrated in the basal metazoan Hydra vulgaris .

How can I effectively detect protein-protein interactions between TERB2 and its binding partners in living cells?

For studying TERB2 interactions in living cells:

• Bimolecular fluorescence complementation (BiFC):

  • Fuse TERB2 and potential binding partners to complementary fragments of a fluorescent protein

  • This approach has successfully mapped the interaction between TERB1 and TERB2

  • The N-terminal domain of TERB2 (residues 1-116) interacts with TERB1 (residues 587-636)

  • The C-terminal fragment of TERB2 (residues 168-202) interacts with MAJIN

• Fluorescence resonance energy transfer (FRET):

  • Tag TERB2 and binding partners with appropriate FRET pairs

  • Useful for analyzing the dynamics of interactions during meiotic progression

• Live-cell imaging:

  • Co-express TERB2 with TERB1 and MAJIN in cellular models

  • MAJIN shows nuclear membrane localization in U-2 OS cells

  • TERB2 when expressed alone displays diffused distribution

  • MAJIN can recruit co-expressed TERB2 to the nuclear membrane

Experimental evidence suggests that expressing mCherry-MAJIN, FLAG-TERB1, and GFP-TERB2 in cells allows visualization of these interaction dynamics .

What are the critical considerations when designing mutational studies to investigate TERB2 function?

For effective TERB2 mutational studies:

Critical considerations include:

• Target selection:

  • Focus on highly conserved residues (Tyr56 and Phe192 are conserved across species)

  • Target residues at the core of protein-protein interfaces

  • Consider the crystal structure of complexes to identify critical interaction sites

• Mutation strategy:

  • Design mutations that introduce charge reversal or steric hindrance

  • Y56E mutation generates an electrostatically unfavorable clash in the TERB1-TERB2 interface

  • F192R substitution disrupts the hydrophobic pocket at the TERB2-MAJIN interface

• Validation approaches:

  • Confirm specific disruption of one interaction without affecting others

  • Y56E mutation only disrupts TERB2 interaction with TERB1 but not with MAJIN

  • F192R mutation only affects interaction with MAJIN but not with TERB1

• In vivo confirmation:

  • Generate mouse models with specific mutations using CRISPR-Cas9

  • Analyze meiotic phenotypes in heterozygous and homozygous animals

How can I design experiments to investigate the role of TERB2 in telomere-nuclear envelope attachment during meiosis?

To study TERB2's role in telomere-nuclear envelope attachment:

• Mouse models:

  • Generate TERB2 knockout or specific mutant mice using CRISPR-Cas9

  • Create targeted mutations that specifically disrupt TERB1-TERB2 (Y56E) or TERB2-MAJIN (F192R) interactions

  • Analyze meiotic progression in these models

• Cellular analyses:

  • Perform immunofluorescence on spread spermatocytes to visualize telomere attachment

  • Co-stain with markers for:

    • Telomeres (TRF1)

    • Nuclear envelope (Lamin B1)

    • Synaptonemal complex (SYCP3)

    • Other meiotic telomere complex components (TERB1, MAJIN)

• Electron microscopy:

  • Use transmission electron microscopy to visualize attachment plates at the ultrastructural level

  • Immunogold labeling with TERB2 antibodies can confirm protein localization

• Functional assays:

  • Monitor telomere movement using live-cell imaging in cultured spermatocytes

  • Assess homologous chromosome pairing and synapsis in mutant models

Research has shown that specific disruption of the TERB1-TERB2 or TERB2-MAJIN interaction abolishes telomere attachment to the nuclear envelope and causes aberrant homologous pairing and disordered synapsis .

What are the most common issues with TERB2 antibodies in western blotting and how can I resolve them?

Common issues and solutions for TERB2 western blotting:

• Weak or no signal:

  • Increase antibody concentration or incubation time

  • Use enhanced chemiluminescence detection systems

  • Consider tissue-specific expression - TERB2 is primarily expressed in testis

  • Verify sample preparation from appropriate developmental stages

  • Use fresh tissue samples when possible

• Multiple bands or non-specific binding:

  • Increase blocking time or change blocking agent

  • Optimize antibody dilution through titration experiments

  • Increase wash stringency with higher salt concentration

  • Verify antibody specificity through knockout controls

  • Consider the possibility of TERB2 isoforms or post-translational modifications

• High background:

  • Increase blocking time and washing steps

  • Decrease primary and secondary antibody concentrations

  • Use highly purified antibody preparations

  • Pre-adsorb antibody with non-specific proteins

• Inconsistent results:

  • Standardize protein extraction methods for testicular tissue

  • Include positive control samples (mouse testis)

  • Use freshly prepared buffers and reagents

How can I optimize TERB2 antibody conditions for chromatin immunoprecipitation (ChIP) experiments?

For successful TERB2 ChIP experiments:

• Crosslinking optimization:

  • Test different formaldehyde concentrations (0.5-2%)

  • Consider dual crosslinking with ethylene glycol bis(succinimidyl succinate) (EGS) before formaldehyde

  • Optimize crosslinking time (5-15 minutes)

• Chromatin fragmentation:

  • Test different sonication conditions for optimal fragment size (200-500 bp)

  • Verify fragmentation efficiency by agarose gel electrophoresis

  • Consider micrococcal nuclease digestion as an alternative method

• Antibody selection:

  • Use ChIP-validated TERB2 antibodies when available

  • Test different epitope targets (N-terminal vs. C-terminal)

  • Try polyclonal antibodies for better epitope coverage

• Controls and validation:

  • Include input chromatin control (5-10%)

  • Use IgG negative control

  • Include positive control targets (telomeric regions)

  • Use quantitative PCR for specific telomeric regions

  • Validate findings with alternative TERB2 antibodies

• Data analysis:

  • Focus on telomeric regions for enrichment analysis

  • Compare enrichment patterns with TRF1 and other telomere-binding proteins

  • Consider the dynamic nature of TERB2-DNA interactions during meiotic progression

Research has shown that the MAJIN-TERB2 2:2 hetero-tetramer binds strongly to DNA with no overt sequence specificity for telomere repeats .

How might TERB2 antibodies contribute to understanding infertility in clinical settings?

TERB2 antibodies could advance clinical infertility research through:

• Diagnostic applications:

  • Immunohistochemical analysis of testicular biopsies from NOA patients

  • Screening for TERB2 expression abnormalities in infertile men

  • Development of diagnostic panels combining TERB2 with other meiotic markers

• Mechanism elucidation:

  • Investigating the impact of TERB2 variants identified in NOA patients

  • The compound heterozygous frameshift variants in TERB2 (c.[457_458del]; [544dup;547_551del]) identified in three NOA brothers provide a starting point

  • Determining if TERB2 mutations affect specific stages of spermatogenesis

• Therapeutic development:

  • Target identification for potential fertility treatments

  • Screening compounds that might stabilize mutant TERB2 function

• Patient stratification:

  • Classifying NOA patients based on molecular defects

  • Predicting outcomes of testicular sperm extraction procedures

Research has identified NOA patients with biallelic variants in all three MTC genes (TERB1, TERB2, and MAJIN), suggesting a common mechanism underlying certain forms of male infertility .

What are the implications of recent structural studies of the TERB2 complex for antibody development?

Recent structural insights have important implications for TERB2 antibody development:

• Structure-guided epitope selection:

  • The crystal structure of MAJIN-TERB2 reveals a 2:2 heterotetramer where two TERB2 chains wrap around a core MAJIN globular dimer

  • Target accessible epitopes outside the TERB1-TERB2 and TERB2-MAJIN interfaces

  • The β-grasp fold of MAJIN with TERB2 chains following a meandering path creates unique structural epitopes

• Conformation-specific antibodies:

  • Develop antibodies specific to TERB2 in complex with TERB1 or MAJIN

  • Target the distinct conformational states during meiotic progression

  • The displacement of TRF1 during pachytene allows MAJIN-TERB2-TERB1 to bind telomeric DNA directly

• Functional domain targeting:

  • Generate antibodies against the N-terminal TERB2 domain (aa 1-116) for studying TERB1 interactions

  • Target the C-terminal region (aa 168-202) for MAJIN interaction studies

  • Develop antibodies against the [F/YxLxP] motif (positions 86-90) for investigating potential TRF1/TRF2 interactions

• Species considerations:

  • The high conservation of functional domains suggests cross-reactivity potential

  • Epitopes in divergent regions might provide species-specific antibodies

The molecular architecture of the meiotic telomere complex revealed through these structural studies provides a framework for more targeted and functional antibody development .

How can computational approaches improve TERB2 antibody design and validation?

Computational methods can enhance TERB2 antibody development:

• Epitope prediction:

  • Utilize crystal structures of TERB2 complexes to identify exposed surface residues

  • Apply machine learning algorithms to predict immunogenic epitopes

  • Model the accessibility of epitopes in different TERB2 conformational states

• Antibody design tools:

  • Implement RosettaAntibodyDesign (RAbD) for in silico antibody modeling

  • Assess binding energy through computational docking studies

  • Design experiments with multiple antibody candidates (>20 designs for redesign projects)

• Validation strategy optimization:

  • Simulate antibody-antigen interactions to predict cross-reactivity

  • Model the impact of mutations in TERB2 on antibody binding

  • Develop computational workflows for distinguishing specific from non-specific signals

• Limitations and considerations:

  • Computational protein design remains challenging, especially for one-sided interface design

  • Success rates for computational antibody design vary widely

  • Redesign of existing antibodies has higher success rates than de novo design

  • Computational predictions should always be validated experimentally